Logo image of LQDA

LIQUIDIA CORP (LQDA) Stock Fundamental Analysis

USA - NASDAQ:LQDA - US53635D2027 - Common Stock

22.02 USD
-0.32 (-1.43%)
Last: 10/23/2025, 8:00:01 PM
22.7125 USD
+0.69 (+3.14%)
After Hours: 10/23/2025, 8:00:01 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to LQDA. LQDA was compared to 191 industry peers in the Pharmaceuticals industry. LQDA has a bad profitability rating. Also its financial health evaluation is rather negative. LQDA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year LQDA has reported negative net income.
LQDA had a negative operating cash flow in the past year.
LQDA had negative earnings in each of the past 5 years.
LQDA had a negative operating cash flow in each of the past 5 years.
LQDA Yearly Net Income VS EBIT VS OCF VS FCFLQDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -54.96%, LQDA is not doing good in the industry: 61.78% of the companies in the same industry are doing better.
The Return On Equity of LQDA (-931.40%) is worse than 80.63% of its industry peers.
Industry RankSector Rank
ROA -54.96%
ROE -931.4%
ROIC N/A
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
LQDA Yearly ROA, ROE, ROICLQDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200

1.3 Margins

Looking at the Gross Margin, with a value of 69.29%, LQDA is in the better half of the industry, outperforming 76.96% of the companies in the same industry.
In the last couple of years the Gross Margin of LQDA has declined.
LQDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
LQDA Yearly Profit, Operating, Gross MarginsLQDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

3

2. Health

2.1 Basic Checks

LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LQDA has been increased compared to 1 year ago.
Compared to 5 years ago, LQDA has more shares outstanding
Compared to 1 year ago, LQDA has a worse debt to assets ratio.
LQDA Yearly Shares OutstandingLQDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
LQDA Yearly Total Debt VS Total AssetsLQDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of 0.08, we must say that LQDA is in the distress zone and has some risk of bankruptcy.
LQDA has a Altman-Z score (0.08) which is in line with its industry peers.
LQDA has a Debt/Equity ratio of 9.84. This is a high value indicating a heavy dependency on external financing.
LQDA's Debt to Equity ratio of 9.84 is on the low side compared to the rest of the industry. LQDA is outperformed by 81.68% of its industry peers.
Industry RankSector Rank
Debt/Equity 9.84
Debt/FCF N/A
Altman-Z 0.08
ROIC/WACCN/A
WACC8.64%
LQDA Yearly LT Debt VS Equity VS FCFLQDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

2.3 Liquidity

LQDA has a Current Ratio of 2.49. This indicates that LQDA is financially healthy and has no problem in meeting its short term obligations.
LQDA has a Current ratio (2.49) which is comparable to the rest of the industry.
LQDA has a Quick Ratio of 2.41. This indicates that LQDA is financially healthy and has no problem in meeting its short term obligations.
LQDA's Quick ratio of 2.41 is in line compared to the rest of the industry. LQDA outperforms 49.74% of its industry peers.
Industry RankSector Rank
Current Ratio 2.49
Quick Ratio 2.41
LQDA Yearly Current Assets VS Current LiabilitesLQDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

LQDA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -8.28%.
Looking at the last year, LQDA shows a very strong growth in Revenue. The Revenue has grown by 30.18%.
Measured over the past years, LQDA shows a quite strong growth in Revenue. The Revenue has been growing by 11.64% on average per year.
EPS 1Y (TTM)-8.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.43%
Revenue 1Y (TTM)30.18%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%141.51%

3.2 Future

LQDA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.04% yearly.
LQDA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 112.61% yearly.
EPS Next Y1.83%
EPS Next 2Y55.87%
EPS Next 3Y41.6%
EPS Next 5Y34.04%
Revenue Next Year336.74%
Revenue Next 2Y354.96%
Revenue Next 3Y200.71%
Revenue Next 5Y112.61%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LQDA Yearly Revenue VS EstimatesLQDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
LQDA Yearly EPS VS EstimatesLQDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LQDA. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 30.70, the valuation of LQDA can be described as expensive.
LQDA's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. LQDA is cheaper than 71.73% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of LQDA to the average of the S&P500 Index (23.33), we can say LQDA is valued slightly more expensively.
Industry RankSector Rank
PE N/A
Fwd PE 30.7
LQDA Price Earnings VS Forward Price EarningsLQDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LQDA Per share dataLQDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
LQDA's earnings are expected to grow with 41.60% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y55.87%
EPS Next 3Y41.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LQDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIQUIDIA CORP

NASDAQ:LQDA (10/23/2025, 8:00:01 PM)

After market: 22.7125 +0.69 (+3.14%)

22.02

-0.32 (-1.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-11 2025-11-11/amc
Inst Owners69.33%
Inst Owner Change-0.01%
Ins Owners4.02%
Ins Owner Change0.31%
Market Cap1.90B
Revenue(TTM)19.32M
Net Income(TTM)-141470000
Analysts82.67
Price Target37.4 (69.85%)
Short Float %25.34%
Short Ratio6.22
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.21%
Min EPS beat(2)-11.43%
Max EPS beat(2)-10.99%
EPS beat(4)1
Avg EPS beat(4)-5.41%
Min EPS beat(4)-20.44%
Max EPS beat(4)21.21%
EPS beat(8)1
Avg EPS beat(8)-22.41%
EPS beat(12)3
Avg EPS beat(12)-20.21%
EPS beat(16)4
Avg EPS beat(16)-22.79%
Revenue beat(2)1
Avg Revenue beat(2)53.95%
Min Revenue beat(2)-6.33%
Max Revenue beat(2)114.23%
Revenue beat(4)2
Avg Revenue beat(4)18.55%
Min Revenue beat(4)-37.8%
Max Revenue beat(4)114.23%
Revenue beat(8)2
Avg Revenue beat(8)-5.54%
Revenue beat(12)5
Avg Revenue beat(12)0.3%
Revenue beat(16)9
Avg Revenue beat(16)2.3%
PT rev (1m)0%
PT rev (3m)21.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.91%
EPS NY rev (1m)-1.05%
EPS NY rev (3m)-1.67%
Revenue NQ rev (1m)2.73%
Revenue NQ rev (3m)75.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)74.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 30.7
P/S 98.11
P/FCF N/A
P/OCF N/A
P/B 124.81
P/tB 230.23
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)0.72
Fwd EY3.26%
FCF(TTM)-1.44
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS0.22
BVpS0.18
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.96%
ROE -931.4%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.29%
FCFM N/A
ROA(3y)-51.66%
ROA(5y)-50.39%
ROE(3y)-127.25%
ROE(5y)-103.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.82%
GM growth 5Y-8.41%
F-Score2
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 9.84
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 425.91%
Cap/Sales 41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.49
Quick Ratio 2.41
Altman-Z 0.08
F-Score2
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)306.37%
Cap/Depr(5y)189%
Cap/Sales(3y)42.88%
Cap/Sales(5y)46.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.43%
EPS Next Y1.83%
EPS Next 2Y55.87%
EPS Next 3Y41.6%
EPS Next 5Y34.04%
Revenue 1Y (TTM)30.18%
Revenue growth 3Y2.89%
Revenue growth 5Y11.64%
Sales Q2Q%141.51%
Revenue Next Year336.74%
Revenue Next 2Y354.96%
Revenue Next 3Y200.71%
Revenue Next 5Y112.61%
EBIT growth 1Y-42.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.15%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-384.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-375.63%
OCF growth 3YN/A
OCF growth 5YN/A